Related Experiment Video
Updated: Jun 17, 2026

09:49
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
Published on: November 20, 2018
Multiscale simulations reveal the driving forces underlying V337M-induced tau core fragment aggregation
Pengxuan Xia1, Yujie Chen2, Jiaxing Tang3
1Department of Sport and Exercise Science, College of Education, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China.
Nanoscale
|June 16, 2026
Summary
The V337M mutation in microtubule-associated protein tau (MAPT) accelerates tau aggregation by enhancing beta-sheet structures and promoting peptide interactions. This molecular insight aids understanding of tauopathy pathogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Biophysics
Background:
- Pathogenic mutations in microtubule-associated protein tau (MAPT) are key drivers of tauopathies.
- The V337M mutation within the PHF6** motif accelerates tau assembly, but its mechanism remains elusive.
Purpose of the Study:
- To elucidate the molecular mechanism by which the V337M mutation influences the conformational ensemble and aggregation behavior of PHF6** peptides.
Main Methods:
- Multiscale molecular dynamics simulations, including replica-exchange, conventional, and coarse-grained approaches.
- Analysis of conformational changes, beta-structure content, and interpeptide interactions.
Main Results:
- V337M mutation enhances beta-sheet structure and promotes compact oligomer formation.
- The mutation strengthens hydrogen bonds, salt-bridges, and residue-residue associations.
- V337M stabilizes persistent oligomerization and interconnected beta-sheet assemblies.
Conclusions:
- Beta-structure formation is essential for PHF6** oligomerization.
- The V337M mutation stabilizes interpeptide associations, leading to accelerated and more extensive oligomer formation.
- Mechanistic insights into mutation-driven tau oligomerization may advance understanding of tauopathy pathogenesis.
Related Concept Videos
SNAREs and Membrane Fusion
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

